Â鶹Éç

The U.S. Food and Drug Administration (FDA) has lifted its clinical hold on the Phase 1/2 trial testing SGT-001, Solid Biosciences’ investigational gene therapy for people with Duchenne muscular dystrophy (Â鶹Éç), the company announced. Updated safety and effectiveness data for all patients dosed to date,…

A single dose of SRP-9001, Sarepta Therapeutics’ investigational gene therapy for  Duchenne muscular dystrophy (Â鶹Éç), continues to be safe and to improve motor function in four boys treated two years ago, according to data from an ongoing Phase 1/2 trial. Updated results from Study-101 (…

Italfarmaco has now completed recruitment — delayed in the spring due to the COVID-19 pandemic — of boys with Duchenne muscular dystrophy (Â鶹Éç) for its ongoing Phase 3 trial of givinostat, according to a top company officer. In another milestone, Givinostat has “just received” rare pediatric disease…

It took one year for Dona Krystosek to get a diagnosis for her son, Levi, after he was born. The family received three misdiagnoses of fatal diseases until they found out Levi has Jansen’s metaphyseal chondrodysplasia — an extremely rare form of dwarfism.   “The hardest…

The experimental therapy vamorolone can improve motor function significantly in boys with Duchenne muscular dystrophy (Â鶹Éç), without stunting their growth and with fewer side effects compared to standard corticosteroids, according to 18-month data from a Phase 2 trial and its extension study. Findings were reported in the study, “…

In a Facebook Live event hosted by the Muscular Dystrophy Association (Â鶹Éç), experts discussed the effect that the COVID-19 pandemic has had on research efforts in muscular dystrophy, as well as the ongoing development of a potential COVID-19 vaccine. Clinical trials are a critical…

Real-world and natural history data could be used to supplement, or perhaps replace, the use of a placebo in future clinical trials in people with Duchenne muscular dystrophy (Â鶹Éç), a new study suggests. The study, “Suitability of external controls for drug evaluation in Duchenne muscular dystrophy,”…

Sarepta Therapeutics has completed a meeting with the Office of Tissues and Advanced Therapies (OTAT) that clarified regulatory requirements to start the company’s next clinical trial of SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (Â鶹Éç). During the type C “written response only” meeting, the…

An imbalance in cells producing proteins called aldehyde dehydrogenases (ALDHs) — favoring fat formation in tissue — is evident in the muscles of people with Duchenne muscular dystrophy (Â鶹Éç), a study reports. A better understanding of these cells could open new avenues of treatment, its researchers said. The…

Santhera Pharmaceuticals has obtained the worldwide rights to vamorolone (VBP15), an experimental therapy for Duchenne muscular dystrophy (Â鶹Éç), the company announced. The company has reached an agreement with ReveraGen Biopharma, the original developer of vamorolone, and Actelion Pharmaceuticals’ spin-off Idorsia, which had acquired an…